Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test

Sergio Szvalb, Moshe Stein, Anthony Gershuny, Eli Gez, Amram Hadary, Jamal Zidan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

HER-2 is overexpressed in 25% of breast cancers and provides a poor prognostic factor, affecting treatment decisions including administration of trastuzumab. Single reports show a lack of HER-2 in non-Hodgkin lymphomas (NHLs) using immunohistochemical (IHC) test. The present study evaluates HER-2 in NHLs using the chromogenic in situ hybridisation (CISH) test, which is more accurate than IHC, to seek new prognostic factors. The secondary aim of the study is to investigate efficacy of using trastuzumab in the treatment of NHLs in future studies. Fifty eight formalin-fixed, paraffin-embedded tissue specimens presenting various NHLs were examined using CISH test. Sixty six percent of all patients were diagnosed at stages III and IV. Histologically, 30 (52%) were low grade and 28 (48%) were intermediate and high grade. HER-2 was negative in all NHLs. Because there is no HER-2 gene amplification in NHL, HER-2 cannot be used as a prognostic factor and should not play a role in biological targeting therapy in non-Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)736-740
Number of pages5
JournalLeukemia and Lymphoma
Volume50
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

Keywords

  • CISH test
  • HER-2
  • Non-Hodgkin lymphoma
  • Prognostic factors

Fingerprint

Dive into the research topics of 'Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test'. Together they form a unique fingerprint.

Cite this